APD 209

Drug Profile

APD 209

Alternative Names: ADE CTP-12-001; APD-209; Trisialic acid compound

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator Adenovir Pharma
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Infectious keratoconjunctivitis

Most Recent Events

  • 29 Apr 2016 Adenovir Pharma completes a phase IIa trial in Infectious keratoconjunctivitis in Germany, Poland and Germany(Ophthalmic)
  • 15 Mar 2016 Biomarkers information updated
  • 19 Feb 2016 Adenovir Pharma has patent protection for APD 209 in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top